After tweaking the formula behind an mRNA flu vaccine, Moderna has finally met all the goals needed for a successful shot in a phase 3 trial. Now, CEO Stéphane Bancel is eyeing a launch as early as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback